RxDoctor Payments Data

Wendy Lawless

Family · Bluefield, VANPI 1073149407

Payments from drug & device makers

$1,257in general payments, 2019–2025

Across 73 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$328
  • Boehringer Ingelheim$241
  • Novo Nordisk$209
  • Lilly USA, LLC$158
  • AstraZeneca$89
  • GSK$52
  • plus $178 from 8 others

What the payments were for

  • Food & beverage$1,257100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,257 in reported general payments places this provider in the 75th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$13,754
Medicare patients
42
Services billed
281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide22$22,633
FarxigaDapagliflozin Propanediol14$16,293
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,768
Albuterol Sulfate HfaAlbuterol Sulfate46$1,267
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic11$640
Insulin SyringeSyringe And Needle,insulin,1ml12$536
Levothyroxine Sodium48$507
Omeprazole38$502
Colchicine13$389
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst15$306
Potassium Chloride27$305
Duloxetine Hcl19$299
Famotidine23$266
Gabapentin26$251
Metoprolol Succinate16$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$158$22,63322 claims
AstraZenecaFarxiga$89$16,29314 claims
GSKTrelegy Ellipta$52$10,76811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,332 family providers in Virginia.

Other family in Bluefield

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →